World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
61265
World Ranking
8114
National Ranking
795

Ian W. Flinn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ian W. Flinn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 716 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ian W. Flinn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ian W. Flinn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ian W. Flinn is affiliated with the Sarah Cannon Research Institute in the United Kingdom. Their research primarily focuses on the field of medicine, with significant contributions across several subfields including genetics, pathology and forensic medicine, oncology, immunology, and hematology.

The scientist's research addresses a variety of topics, with particular attention to chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, and CAR-T cell therapy research. Additional topics of interest include chronic myeloid leukemia treatments, biosimilars and bioanalytical methods, monoclonal and polyclonal antibodies research, and immunodeficiency and autoimmune disorders.

Recent publications by Ian W. Flinn include:

  • KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma, 2020, New England Journal of Medicine
  • Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial, 2020, The Lancet
  • Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study, 2021, The Lancet

The scientist collaborates frequently with several coauthors, including Wojciech Jurczak, Paolo Ghia, Jeff P. Sharman, Constantine S. Tam, and Nirav N. Shah.

Ian W. Flinn is also a frequent contributor to multiple academic journals. The most common publication venues are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere
  • Hematological Oncology

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

    Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael Wang;Javier Munoz;Andre Goy;Frederick L. Locke

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

    Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides

  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

    A. Hochhaus;G. Saglio;Timothy Hughes;R. A. Larson

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

    Hagop M. Kantarjian;Andreas Hochhaus;Giuseppe Saglio;Carmino De Souza

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

    John C. Byrd;Timothy Murphy;Robin S. Howard;Margaret S. Lucas

  • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Gerard Lozanski;Nyla A. Heerema;Ian W. Flinn;Lisa Smith

  • Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

    Ian W. Flinn;Donna S. Neuberg;Michael R. Grever;Gordon W. Dewald

  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

    Eytan M. Stein;Courtney Denton Dinardo;Daniel Aaron Pollyea;Amir Tahmasb Fathi

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Steven Coutre
Steven Coutre Stanford University
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Susan O'Brien
Susan O'Brien University of California, Irvine
John P. Leonard
John P. Leonard Cornell University
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
John G. Gribben
John G. Gribben Queen Mary University of London
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring a career in medicine, a variety of online degree options and alternative paths are available to help you reach your goals. For those interested in advanced nursing but don’t hold a nursing background, consider direct entry np programs for non nurses online. These programs enable career changers to become nurse practitioners more quickly by providing a streamlined route into the field.

Entry into traditional nursing programs can be highly competitive, but some nursing schools with high acceptance rates offer more accessible pathways. These schools may be ideal for students seeking flexible options and a supportive admission process.

Beyond nursing, other healthcare roles such as medical billing and coding are also in demand. Many accredited institutions offer online medical billing and coding with financial aid, making it easier to start a healthcare career without a clinical background.

Some nursing programs reduce barriers even further by offering enrollment with no standardized exam requirements. Consider a nursing school no entrance exam to streamline your application process and begin your studies sooner.

Best Scientists Citing Ian W. Flinn

Trending Scientists

Recently Published Articles